0
0.0
Feb 8, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
and then vertex pharmaceuticals, talk about pfizer, how about vertex? it fell after earnings this week. so are investors getting a buying opportunity, which has been the case every time it's fallen? i'm going to sit down with the ceo and get the latest. so stay with cramer. >> announcer: don't miss a second of "mad money." follow @jimcramer on x. have a question? tweet cramer. #madmentions. send jim an e-mail to madmoney@cnbc.com. or give us a call at 1-800-743-cnbc. miss something? head to madmoney.cnbc.com. ♪ ♪ every day, businesses everywhere are asking: is it possible? with comcast business... it is. is it possible to help keep our online platform safe from cyberthreats? absolutely. can we provide health care virtually anywhere? we can help with that. is it possible to use predictive monitoring to address operations issues? we can help with that, too. with the advanced connectivity and intelligence of global secure networking from comcast business. it's not just possible. it's happening. that first time you take a step back. i made that. with your v
and then vertex pharmaceuticals, talk about pfizer, how about vertex? it fell after earnings this week. so are investors getting a buying opportunity, which has been the case every time it's fallen? i'm going to sit down with the ceo and get the latest. so stay with cramer. >> announcer: don't miss a second of "mad money." follow @jimcramer on x. have a question? tweet cramer. #madmentions. send jim an e-mail to madmoney@cnbc.com. or give us a call at 1-800-743-cnbc. miss...
0
0.0
Feb 23, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
vertex -- lists for over 2 million.for over 3 million. >> i do have insurance, but those, i mean i already have medical bills. >> good wins hesitancy doesn't surprise dr. julie kanter, director of the adult sickle cell center at the university of alabama and birmingham. >> my guess is that even if we opened the gates today to everyone getting its -- . at most, only 10% of those individuals affected by sickle cell would want this therapy. and, even that will be too much for us to manage right the second. >> more than 100,000 americans have sickle cell disease, according to the cdc, with 50 to 60% of them covered by medicaid. doctor kanter says it will take time to wrap up capacity to treat patients at scale. in the meantime, states are grappling with how to ramp up access, for those on medicaid. >> the immediate consideration is the cost. it is very high, and state budgets simply cannot manage that on their own. >> the biden administration is launching negotiations with -- and vertex for medicate planned discounts with p
vertex -- lists for over 2 million.for over 3 million. >> i do have insurance, but those, i mean i already have medical bills. >> good wins hesitancy doesn't surprise dr. julie kanter, director of the adult sickle cell center at the university of alabama and birmingham. >> my guess is that even if we opened the gates today to everyone getting its -- . at most, only 10% of those individuals affected by sickle cell would want this therapy. and, even that will be too much for us...
0
0.0
Feb 15, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
i like vertex. i think he should look at vertex. that's a terrific company.t forget, you do want to have a diversified portfolio. it's okay to be able to take a look at some of the stocks that you and i both know like i ahoneywell is still incredibly cheap that we have. and maybe you have a stock that's a bit of a flyer like a foot locker. so build a diversified portfolio but emphasize the science, i think you'll be in good shape. now we'regoing to go to vincent in new york. vincent. >> caller: hey, cramer. how are you? >> i'm good, vincent. how are you? >> caller: i'm well. what advice would you give a 26-year-old that's been day trading for about two years and is looking to, you know, do better and go as far with this as he can? >> if you're day trading it's a full-time occupation. so what you want to do is put some money in the vanguard total return fund and put some money in the vanguard s&p 500 fund and just keep putting money away every single month. if you have some good day trades and you made a lot of money, take off some of that capital and put it i
i like vertex. i think he should look at vertex. that's a terrific company.t forget, you do want to have a diversified portfolio. it's okay to be able to take a look at some of the stocks that you and i both know like i ahoneywell is still incredibly cheap that we have. and maybe you have a stock that's a bit of a flyer like a foot locker. so build a diversified portfolio but emphasize the science, i think you'll be in good shape. now we'regoing to go to vincent in new york. vincent. >>...
0
0.0
Feb 5, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
. >> vertex, that stock is up 30%, no slouch. you own that?ve a new pain medicine, and they are a cystic fibrosis franchise is unasalable, and other diseases like type one. that's close to my heart. >> lilly, a new all-time high for this stock. >> steve talked about it. momentum is alive and well in the market, and lilly is a prime example of that. i won't speak about the technicals. we know how strong they are. on the fundamental side, can they raise guidance and what can they say about lilly direct? >> you want to speak about chipotle? >> yeah, the price hike has clearly been something that has been passed on to the consumers with no concern whatsoever. what they report in terms of margins and the brand value of this company is absolutely remarkable. >> let's jump to cvs? >> yeah, i think if they can in any way do better than expectations, the stock will pop. still cheap, great cash flow and a nice tkdividend. >> and then xpo? >> yeah, it has done well, and i will look at what they talk about, supply chain, freight costs, and if you have any
. >> vertex, that stock is up 30%, no slouch. you own that?ve a new pain medicine, and they are a cystic fibrosis franchise is unasalable, and other diseases like type one. that's close to my heart. >> lilly, a new all-time high for this stock. >> steve talked about it. momentum is alive and well in the market, and lilly is a prime example of that. i won't speak about the technicals. we know how strong they are. on the fundamental side, can they raise guidance and what can...
0
0.0
Feb 6, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
. >> other stocks that are moving, vertex did beat on the top and the bottom line. shares were down at print. let's look at where we are on one of jimmy's stocks. what about this, jim? >> profit taking. this was fabulous. cystic fibrosis is its main market but they're moving into pain medication. for a pain medication that's not addictive but looks like it's as effective as opioids. the future is very bright for this company. >> ge health care, steph. they beat on both the top and the bottom. >> finally. organic growth was good. they were up 60 basis points and guided going forward. better top line, better earnings. >> nxp, shares were up modestly. revenue barely ahead of consensus, challenging semiconductor market. the stock is hanging on a little bit. a well-run company. management works hard to manage inventory. they don't want to find customers have a glut of inventory and pricing goes down. the first half of the year, particularly in automotive, will be tepid. the second half shows strong growth. i agree. everybody knows, i think, my position on automotive, we
. >> other stocks that are moving, vertex did beat on the top and the bottom line. shares were down at print. let's look at where we are on one of jimmy's stocks. what about this, jim? >> profit taking. this was fabulous. cystic fibrosis is its main market but they're moving into pain medication. for a pain medication that's not addictive but looks like it's as effective as opioids. the future is very bright for this company. >> ge health care, steph. they beat on both the top...
0
0.0
Feb 29, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
just had a drug approved for sickle cell disease, a more well-known rare disease, with our partner, vertext is just the start. with the crisper technology, it is a programmable and scalable platform which connects to many bridges eases and provides transformative treatment for these where diseases. >> when it comes to what you're expecting going forward, what will we look forward to? give us good news on the horizon. is the research that is getting close to offer a new treatments for some of these individuals? >> yes, scott will attest that the science is moving at breakneck speed. it is not just crispr therapeutics but other companies in the space as well, doing work with rare diseases. we are working with a number of rare diseases, for instance, rare forms of cancer like t cell lymphoma's, type two diabetes, we are autoimmune diseases like lupus neuritis and also neuromuscular diseases. the science is moving forward very quickly. the editing is working. we are able to take this crispr tool and apply it to specific locations on the genome and make a precise added to that fundamentally fix
just had a drug approved for sickle cell disease, a more well-known rare disease, with our partner, vertext is just the start. with the crisper technology, it is a programmable and scalable platform which connects to many bridges eases and provides transformative treatment for these where diseases. >> when it comes to what you're expecting going forward, what will we look forward to? give us good news on the horizon. is the research that is getting close to offer a new treatments for some...
0
0.0
Feb 5, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
vertex pharma higher. 17% after the company posted earnings in line with estimates, but beat revenues. and shares of tesla dropped 4% today. reports over the weekend saying ceo elon musk pressured tesla board members to do drugs with him. report saying some directors felt there was an expectation to use the drugs to avoid upsetting musk. you say this is sort of the reckoning for musk at this point? >> listen, on a day like today, the stock was down nearly 7%. you say to yourself, okay, is he selling stock again? there's been odd pressure, you know, couldn't sell stock in the leadup to their quarter. you know, did he have margin calls? we know he's pledged most of his shares for the twitter acquisition and the like here. maybe investors are starting to price what tesla after musk really looks like, what the premium that's built in there for him, so, i mean, the stock, you know, is trading above 250, we talked about a stock that's gained 40% in a straight line. this stock, it really does act like it's coming
vertex pharma higher. 17% after the company posted earnings in line with estimates, but beat revenues. and shares of tesla dropped 4% today. reports over the weekend saying ceo elon musk pressured tesla board members to do drugs with him. report saying some directors felt there was an expectation to use the drugs to avoid upsetting musk. you say this is sort of the reckoning for musk at this point? >> listen, on a day like today, the stock was down nearly 7%. you say to yourself, okay, is...
0
0.0
Feb 27, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
again, it would be regeneron, vertex, moderna. >> carter, thank you so much. carter braxton worth of worth charting. so, if money is going into bio tech, where is the money coming from? jared holz was writing about the bio tech rally this morning, said maybe money is coming from mega cap tech. >> apple. >> apple. >> think about what's not been performing and think about where it is easy to say there is no innovation and i'm not saying that, but we're trying to characterize why someone might rotate out of what is formerly higher growth stuff. it's a big change in allocation. you are taking on more risk, significantly more risk when you are looking at bio tech over an apple or even a google. but i do think a lot of '22, outside of nvidia, lilly, has been broadening and allocation. >> some of these moves are really unabated. if they pull up the xlv, we know what's going on here, this thing is literally -- it's 45 -- it's pretty steep here, right? so, the idea we wouldn't have a check-back, if carter had a little more time, he might say that, things that broke out
again, it would be regeneron, vertex, moderna. >> carter, thank you so much. carter braxton worth of worth charting. so, if money is going into bio tech, where is the money coming from? jared holz was writing about the bio tech rally this morning, said maybe money is coming from mega cap tech. >> apple. >> apple. >> think about what's not been performing and think about where it is easy to say there is no innovation and i'm not saying that, but we're trying to...
0
0.0
Feb 8, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
. >> ge and vertex. >> i want to know about the pain medicines versus opioids. spun off and peter proved them all wrong. i can't wait until tonight's show. i may do nothing except stay here. don't you have the kellogg -- >> and the hershey. >> and hershey. >> what do you think, sara? >> i think i want to know what's going on with the consumer. >> oh. >> why? >> won't leave. >> you can stay. you're welcome. >> do my morning meeting for the cnbc investor club. rene, it's not a short squeeze. it's a legitimate stock that was under valued. >> okay. that is a key question with an enormous move in arm. let's move on to another big move this morning and that is shares of disney, which are up almost 10%. the stock responding to strong quarterly results ahead of expectations, particularly on the cost line. the company also announcing a number of deals and upcoming events, and i'm that includes updates on cost-cutting targets. bob iger told cnbc we still got work to do in light of, of course, that proxy fight that continues with nelson peltz. >> you don't snap your finger
. >> ge and vertex. >> i want to know about the pain medicines versus opioids. spun off and peter proved them all wrong. i can't wait until tonight's show. i may do nothing except stay here. don't you have the kellogg -- >> and the hershey. >> and hershey. >> what do you think, sara? >> i think i want to know what's going on with the consumer. >> oh. >> why? >> won't leave. >> you can stay. you're welcome. >> do my morning...